Breaking News Headlines Today | Ground News

See every side of every news story

Optimum Strategic Communications image

News from Optimum Strategic Communications

Optimum Strategic Communications’s aggregated media bias check is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Optimum Strategic Communications’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Optimum Strategic Communications

Where is Optimum Strategic Communications located?Optimum Strategic Communications's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Optimum Strategic Communications News

Poolbeg Pharma (AIM: POLB) Interim Results for the six months to 30 June 2025

Poolbeg Pharma (AIM: POLB) Interim Results for the six months to 30 June 2025

Well-funded with multiple upcoming clinical milestones 29 September 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces itsRead More...See the Story

Lonza’s Synaffix Collaborates with Qurient Therapeutics on Dual-Payload ADC Development

South Korea · South Korea

Lonza’s Synaffix Collaborates with Qurient Therapeutics on Dual-Payload ADC Development

Synaffix, a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), entered into a licensing agreement with Qurient, a clinical-stage biopharmaceutical company based in South Korea, for the development of a dual-payload ADC. Dual-payload ADCs are designed to deliver two separate cytotoxic agents with distinct mechanisms of action to target cancer cells, aiming to enh…See the Story

Poolbeg Pharma (AIM: POLB) POLB 001 Phase 2a Trial Update

Manchester, England · Manchester

Poolbeg Pharma (AIM: POLB) POLB 001 Phase 2a Trial Update

ACT appointed for POLB 001 Phase 2a Trial and supply of approved bispecific antibody drug secured at no cost Trial to take place at The Christie NHS Foundation Trust and other leading UKRead More...See the Story

Breaking News Topics Related to Optimum Strategic Communications